Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Our pipeline is based on our platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway.
Evidence suggests that potent and selective inhibition of C1q can prevent tissue damage triggered in antibody-mediated autoimmune disease and preserve loss of functioning synapses associated with cognitive and functional decline in complement-mediated neurodegeneration. Our product candidates are designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Sep 30, 2021 at 12:40 PM EDT2021 Cantor Virtual Global Healthcare Conference
Sep 27, 2021 at 10:00 AM EDTAnnexon C1q Series: Neurodegeneration Franchise
Jul 28, 2021 at 10:30 AM EDTAnnexon C1q Series: Autoimmune Portfolio Expansion
Sep 23, 2021 |Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
Sep 20, 2021 |Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
Aug 16, 2021 |Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update